Dublin, Aug. 25, 2017 -- The "United States Insulin Pump Market Size, Share, Opportunity, Analysis, Growth Potential & Demand Forecast 2017 - 2022" report has been added to Research and Markets' offering.
This is the 2nd latest edition report published by the Market Report Publisher. United States Insulin Pump Market Size, Share, Opportunity, Analysis, Growth Potential & Demand Forecast 2017 - 2022 provides a deep and thorough evaluation of the United States Insulin Pump Market. The report provides an in-depth analysis of the type 1, type 2 and newly diagnosed type 1 diabetes and overall diabetes population.
Market growth can be attributed to factors such as increasing number of diabetic patients, growing awareness towards diabetes, improved glucose control and flexible, lifestyle-compatible treatment options and technological advancement in insulin pump devices. However, high cost of the insulin pump devices is expected to hamper growth of the market during forecast period.
It provides essential insights into insulin pump users with more focused on type 1 and type 2 diabetes insulin pump users. Market outlook in value terms has been analysed based on current and potential trends and the market is estimated from 2017 to 2022. Additionally, the report includes assessment of clinical trials and preferred insulin pump brand by the patients. Key trends in terms of collaborations, partnerships and licensing agreements are analysed with details. The report also explores detailed description of growth drivers and inhibitors of the United States Insulin Pump Market.
The report concludes with the profiles of major players in the Insulin Pump Market such as Insulet Corporation, Medtronic, Roche, Animas Corporation and Tandem Diabetes Care. The major market players are evaluated on various parameters such as company overview, product outlook and sales analysis of the Insulin Pump and Diabetes Market from 2011 to 2022.
Key Topics Covered in the Report:
- United States Diabetes Population (2011 - 2022)
- United States Insulin Pump Users and Market Analysis (2011 - 2022)
- United States Insulin Pump Preferred Brand - By Product
- United States Insulin Pump Market: Reimbursement & Regulation System
- United States Insulin Pump Market - Major Deal Types
- Insulin Pump Market Clinical Trail Insight by Phase, Company & Country
- Key Companies Analysis
- Key Drivers and Inhibitors of the United States Insulin Pump Market
Key Companies Covered in the Report are as follows:
- Insulet Corporation
- Medtronic
- Roche
- Animas Corporation and
- Tandem Diabetes Care
Key Topics Covered:
1. Executive Summary
2. United States Diabetes Population (2011 - 2022): An Analysis
2.1 Overall Diabetes Population
2.1.1 Type 1 Diabetes
2.1.2 Type 2 Diabetes
2.1.3 Newly Diagnosed Type 1 Diabetes
3. United States Insulin Pump Market Analysis (2011- 2022)
3.1 Insulin Pump Users
3.1.1 Type 1 Diabetes Insulin Pump Users
3.1.2 Type 2 Diabetes Insulin Pump Users
3.2 Insulin Pump Market
4. Key Drivers and Inhibitors of the United States Insulin Pump Market
4.1 Market Drivers
4.2 Inhibitors
5. United States Insulin Pump Preferred Brand - By Product
5.1 Pediatric
5.2 Adult
6. United States Insulin Pump Market: Reimbursement & Regulation System
6.1 Reimbursement System
6.2 Regulation System
7. United States Insulin Pump Market - Major Deal Types
7.1 Insulin Pump Market - Collaboration Deals
7.2 Insulin Pump Market - Licensing Agreement
7.3 Insulin Pump Market - Exclusive Agreement
7.4 Insulin Pump Market - Partnerships Deals
8. Insulin Pump Market Clinical Trail Insight by Phase, Company & Country
8.1 Year 2016
8.2 Year 2015
8.3 Year 2014
8.4 Year 2013
8.5 Year 2012
9. Key Companies Analysis
- Animas Corporation
- Insulet Corporation
- Medtronic
- Roche
- Tandem Diabetes Care
For more information about this report visit https://www.researchandmarkets.com/research/jzlff3/united_states
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Diabetes Devices , Infusions and Injectables


Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible
Samsung Electronics Shares Jump on HBM4 Mass Production Report
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Washington Post Publisher Will Lewis Steps Down After Layoffs 



